These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37032401)

  • 1. Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial.
    Shao M; Yao J; Wang Y; Zhao L; Li B; Li L; Wu Z; Chen Z; Fan J; Qiu F
    Signal Transduct Target Ther; 2023 Apr; 8(1):146. PubMed ID: 37032401
    [No Abstract]   [Full Text] [Related]  

  • 2. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer.
    Zhang X; Shao M; Yao J; Zhao L; Li L; Chen M; Zhang Y; Liu H; Chen Z; Li B; Wu Z; Fan J; Qiu F
    Future Oncol; 2024 Jan; 20(3):121-129. PubMed ID: 38353107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report.
    Liu Y; Gao Z; Zhang C; Liu X; Liu Z; Lin X; Qian B; Jin F; Shao G; Yang Z
    Anticancer Drugs; 2022 Jan; 33(1):e784-e788. PubMed ID: 34419961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.
    Chaft JE; Rusch V; Ginsberg MS; Paik PK; Finley DJ; Kris MG; Price KA; Azzoli CG; Fury MG; Riely GJ; Krug LM; Downey RJ; Bains MS; Sima CS; Rizk N; Travis WD; Rizvi NA
    J Thorac Oncol; 2013 Aug; 8(8):1084-90. PubMed ID: 23857398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
    Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
    J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer.
    Zhang P; Dai J; Sun F; Xia H; He W; Duan L; Liu M; Zhao D; Zhu Y; Jiang G
    Ann Thorac Surg; 2022 Sep; 114(3):949-958. PubMed ID: 35176262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controversy in the treatment of non-small cell lung cancer. Timing of chemotherapy in relation to surgery: before or after?].
    Dediu M
    Pneumologia; 2004; 53(3):105-8. PubMed ID: 16108158
    [No Abstract]   [Full Text] [Related]  

  • 11. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress of Neoadjuvant Therapy Combined with Surgery in Non-small Cell
Lung Cancer].
    Wang Y; Wang X; Yan S; Yang Y; Wu N
    Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):352-360. PubMed ID: 28532544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
    Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
    Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy in non small cell lung cancer-the UK experience.
    Waller DA
    Lung Cancer; 2001 Dec; 34 Suppl 3():S31-3. PubMed ID: 11740990
    [No Abstract]   [Full Text] [Related]  

  • 15. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-stage lung cancer findings end a debate, put focus on next steps.
    McNeil C
    J Natl Cancer Inst; 2004 Jul; 96(14):1054-5. PubMed ID: 15265961
    [No Abstract]   [Full Text] [Related]  

  • 17. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
    Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
    Tieu BH; Sanborn RE; Thomas CR
    Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.
    Bertino E; Villalona-Calero MA; Ross P; Grever M; Otterson GA
    Ann Thorac Surg; 2011 Feb; 91(2):640. PubMed ID: 21256341
    [No Abstract]   [Full Text] [Related]  

  • 20. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.
    Stefani A; Alifano M; Bobbio A; Grigoroiu M; Jouni R; Magdeleinat P; Regnard JF
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):356-63. PubMed ID: 20381815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.